trending Market Intelligence /marketintelligence/en/news-insights/trending/1z9lsrzgMz7P05dGGK05Wg2 content esgSubNav
In This List

US FDA approves Cadila's generic version of Shire's Lialda

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Blog

Corporate Credit Risk Trends in Developing Markets: A Probability of Default Perspective


US FDA approves Cadila's generic version of Shire's Lialda

The U.S. Food and Drug Administration granted Cadila Healthcare Ltd. approval to market mesalamine delayed release tablets USP, 1.2 grams.

The drug is the first approved generic version of Shire PLC's Lialda, a treatment for mild to moderate ulcerative colitis, a type of chronic inflammatory bowel disease.

Estimated brand sales for mesalamine delayed-release tablets USP 1.2 g is $1.15 billion, per the IMS Health moving annual total as of April.

The generic will be manufactured at Cadila's Moraiya facility in Ahmedabad, India.

In May, the U.S. Court of Appeals for the Federal Circuit ruled that Zydus Pharmaceuticals (USA) Inc.'s generic version of Lialda does not infringe on Shire's patent.